FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046007987> ?p ?o ?g. }

• W3046007987 endingPage "583" @default.
• W3046007987 startingPage "575" @default.
• W3046007987 abstract "Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice.Cross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded.Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 -189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (n = 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5-6 (57.8%) or 7-8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%.Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs." @default.
• W3046007987 created "2020-08-03" @default.
• W3046007987 creator A5000346125 @default.
• W3046007987 creator A5008173875 @default.
• W3046007987 creator A5009662914 @default.
• W3046007987 creator A5011038903 @default.
• W3046007987 creator A5025832509 @default.
• W3046007987 creator A5043211543 @default.
• W3046007987 creator A5047448393 @default.
• W3046007987 creator A5053160121 @default.
• W3046007987 creator A5066796615 @default.
• W3046007987 creator A5067149370 @default.
• W3046007987 creator A5067511457 @default.
• W3046007987 creator A5071169056 @default.
• W3046007987 creator A5087777923 @default.
• W3046007987 date "2020-07-28" @default.
• W3046007987 modified "2023-10-08" @default.
• W3046007987 title "Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly" @default.
• W3046007987 cites W123434114 @default.
• W3046007987 cites W1957506286 @default.
• W3046007987 cites W2012407587 @default.
• W3046007987 cites W2016995223 @default.
• W3046007987 cites W2036119817 @default.
• W3046007987 cites W2036285504 @default.
• W3046007987 cites W2038462595 @default.
• W3046007987 cites W2039973247 @default.
• W3046007987 cites W2052918979 @default.
• W3046007987 cites W2060675452 @default.
• W3046007987 cites W2069900263 @default.
• W3046007987 cites W2070441602 @default.
• W3046007987 cites W2076781582 @default.
• W3046007987 cites W2089075484 @default.
• W3046007987 cites W2098580479 @default.
• W3046007987 cites W2116307557 @default.
• W3046007987 cites W2120786217 @default.
• W3046007987 cites W2126750918 @default.
• W3046007987 cites W2130495579 @default.
• W3046007987 cites W2140643048 @default.
• W3046007987 cites W2145336503 @default.
• W3046007987 cites W2154981330 @default.
• W3046007987 cites W2155465275 @default.
• W3046007987 cites W2163438871 @default.
• W3046007987 cites W2167909460 @default.
• W3046007987 cites W2208042918 @default.
• W3046007987 cites W2277562868 @default.
• W3046007987 cites W2531932518 @default.
• W3046007987 cites W2565789328 @default.
• W3046007987 cites W4292528167 @default.
• W3046007987 doi "https://doi.org/10.1007/s12020-020-02424-z" @default.
• W3046007987 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7674328" @default.
• W3046007987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32725444" @default.
• W3046007987 hasPublicationYear "2020" @default.
• W3046007987 type Work @default.
• W3046007987 sameAs 3046007987 @default.
• W3046007987 citedByCount "12" @default.
• W3046007987 countsByYear W30460079872020 @default.
• W3046007987 countsByYear W30460079872021 @default.
• W3046007987 countsByYear W30460079872022 @default.
• W3046007987 countsByYear W30460079872023 @default.
• W3046007987 crossrefType "journal-article" @default.
• W3046007987 hasAuthorship W3046007987A5000346125 @default.
• W3046007987 hasAuthorship W3046007987A5008173875 @default.
• W3046007987 hasAuthorship W3046007987A5009662914 @default.
• W3046007987 hasAuthorship W3046007987A5011038903 @default.
• W3046007987 hasAuthorship W3046007987A5025832509 @default.
• W3046007987 hasAuthorship W3046007987A5043211543 @default.
• W3046007987 hasAuthorship W3046007987A5047448393 @default.
• W3046007987 hasAuthorship W3046007987A5053160121 @default.
• W3046007987 hasAuthorship W3046007987A5066796615 @default.
• W3046007987 hasAuthorship W3046007987A5067149370 @default.
• W3046007987 hasAuthorship W3046007987A5067511457 @default.
• W3046007987 hasAuthorship W3046007987A5071169056 @default.
• W3046007987 hasAuthorship W3046007987A5087777923 @default.
• W3046007987 hasBestOaLocation W30460079871 @default.
• W3046007987 hasConcept C126322002 @default.
• W3046007987 hasConcept C134018914 @default.
• W3046007987 hasConcept C23131810 @default.
• W3046007987 hasConcept C2776297358 @default.
• W3046007987 hasConcept C2777288759 @default.
• W3046007987 hasConcept C2777433750 @default.
• W3046007987 hasConcept C2779609023 @default.
• W3046007987 hasConcept C2984496839 @default.
• W3046007987 hasConcept C555293320 @default.
• W3046007987 hasConcept C71315377 @default.
• W3046007987 hasConcept C71924100 @default.
• W3046007987 hasConcept C90924648 @default.
• W3046007987 hasConceptScore W3046007987C126322002 @default.
• W3046007987 hasConceptScore W3046007987C134018914 @default.
• W3046007987 hasConceptScore W3046007987C23131810 @default.
• W3046007987 hasConceptScore W3046007987C2776297358 @default.
• W3046007987 hasConceptScore W3046007987C2777288759 @default.
• W3046007987 hasConceptScore W3046007987C2777433750 @default.
• W3046007987 hasConceptScore W3046007987C2779609023 @default.
• W3046007987 hasConceptScore W3046007987C2984496839 @default.
• W3046007987 hasConceptScore W3046007987C555293320 @default.
• W3046007987 hasConceptScore W3046007987C71315377 @default.
• W3046007987 hasConceptScore W3046007987C71924100 @default.
• W3046007987 hasConceptScore W3046007987C90924648 @default.

• next